Analysed EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) News Sources
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
01-04-2026
yahoo.com
Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline
30-03-2026
yahoo.com
Assessing Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term MESA Study Results
16-03-2026
yahoo.com
Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next
16-03-2026
yahoo.com
Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference
16-03-2026
marketbeat.com
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
15-03-2026
fool.com
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
15-03-2026
fool.com
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
10-03-2026
yahoo.com
What is the current price of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)?
The current price of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) is $32.82.
EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) since the previous trading day is $-0.7.
EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) since the previous trading day is -2.0883%.
What is the most recent average sentiment score for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)?
The most recent average sentiment score for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) is 88 out of 100.
What is the most recent average sentiment for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)?
The most recent sentiment for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) is .
SEC-8K** Filing Available For EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.